2
H index
1
i10 index
26
Citations
Université de Bordeaux | 2 H index 1 i10 index 26 Citations RESEARCH PRODUCTION: 4 Articles 74 Papers 1 Chapters RESEARCH ACTIVITY: 12 years (2010 - 2022). See details. MORE DETAILS IN: ABOUT THIS REPORT: Permalink: http://citec.repec.org/pgo436 |
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Philippe GORRY. | Is cited by: | Cites to: |
Journals with more than one article published | # docs |
---|---|
Revue de la Rgulation - Capitalisme, institutions, pouvoirs | 2 |
Scientometrics | 2 |
Working Papers Series with more than one paper published | # docs |
---|---|
Post-Print / HAL | 72 |
Year | Title of citing document |
---|---|
2023 | Altmetrics-based sleeping beauties: necessity or just a supplement?. (2023). Li, Hao ; Hou, Jianhua ; Zhang, Yang. In: Scientometrics. RePEc:spr:scient:v:128:y:2023:i:10:d:10.1007_s11192-023-04798-z. Full description at Econpapers || Download paper |
Year | Title | Type | Cited |
---|---|---|---|
2012 | Construction politique des marchés et politiques des prix. Le cas de lindustrie pharmaceutique In: Post-Print. [Citation analysis] | paper | 0 |
2011 | Regulating the drugs market in the EU: the contradiction between safety, innovation and access to care In: Post-Print. [Citation analysis] | paper | 0 |
2011 | Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS) In: Post-Print. [Citation analysis] | paper | 0 |
2013 | CH2 Une demande structurée par les prescripteur & CH3 Un système dominé par les firmes multinationales pharmaceutiques In: Post-Print. [Citation analysis] | paper | 0 |
2010 | The political construction of orphan drugs market: between innovation & access to care In: Post-Print. [Citation analysis] | paper | 0 |
2010 | Impact of market exclusivity versus IP protection in fostering innovation for rare diseases In: Post-Print. [Citation analysis] | paper | 0 |
2012 | Schéma régional de lenseignement supérieur, de la recherche & de linnovation In: Post-Print. [Citation analysis] | paper | 0 |
2018 | Exploring the historical roots of mesenchymal stem cell research using reference publication year spectroscopy In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Health innovation for rare diseases In: Post-Print. [Citation analysis] | paper | 1 |
2014 | Building an orphan drug market database to enpower decision making by patient organizations & pharma-biotech companies In: Post-Print. [Citation analysis] | paper | 0 |
2014 | Les enjeux de la reconnaissance de la radiologie interventionnelle : un travail de recherche interdisciplinaire (sociologie, économie, droit) In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Construction of mental health categories In: Post-Print. [Full Text][Citation analysis] | paper | 1 |
2015 | Mapping scientific dynamics in « Regenerative Medicine » research, Tissue Engineering Part A, 21, S1 In: Post-Print. [Citation analysis] | paper | 0 |
2014 | Institutionnalisation des politiques publiques de santé & diffusion de l’innovation médicale In: Post-Print. [Citation analysis] | paper | 0 |
2014 | Approche quantitative de la diffusion d’un innovation: exemple de la radiologie interventionnelle In: Post-Print. [Citation analysis] | paper | 0 |
2014 | Institutionalizarion of public policies & diffusion of innovation: the case of interventional radiology In: Post-Print. [Citation analysis] | paper | 0 |
2014 | Diagnostic prénatal non invasif sur sang maternel & Propriété Intellectuelle: entre éthique de la santé et efficience du marché In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Intellectual Property Rights and Traditional Knowledge: to which extend biodiversity is preempted at the global level In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Charles Dotter & the birth of Interventional Radiology: A sleeping beauty with a restless sleep In: Post-Print. [Citation analysis] | paper | 0 |
2015 | L’histoire de la radiologie interventionnelle: développement et diffusion d’une innovation médicale In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies.(2015) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
2018 | Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies.(2018) In: NBER Chapters. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | chapter | |
2017 | Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies..(2017) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
2016 | Serendipity and university technology transfer: a case study. In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Empirical economic analysis of orphan drug legislation impact on innovation In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
2016 | Pharma Competitive Intelligence using open source data and visualization tool: towards metrics for drug R&D milestones In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Biodiversity Sustainability of Phytomedicine Research: a 3-dimensions analysis around the North-South divide In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Empirical Economic Analysis of Orphan Drug Innovation In: Post-Print. [Citation analysis] | paper | 0 |
2017 | Empirical Economic Analysis of Orphan Drug Innovation.(2017) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
2016 | Empirical Economic Analysis of Orphan Drug Innovation.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
2017 | Orphan Drugs: Why the US legislation approves more than the EU? In: Post-Print. [Citation analysis] | paper | 0 |
2017 | Social Recognition of a Medical Innovation: the case of Interventional Radiology in Oncology In: Post-Print. [Citation analysis] | paper | 0 |
2017 | Neologisms and affiliation name: a bibliometric perspective on the institutionalization of interventional radiology In: Post-Print. [Citation analysis] | paper | 0 |
2017 | Evolution des prescriptions de médicaments orphelins en cancérologie : en France, et à l’échelle d’un établissement hospitalier In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Evolution des prescriptions de médicaments orphelins en cancérologie: en France et à l’échelle d’un établissement hospitalier.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
2018 | Orphan Drug Market Exclusivity Extension versus Patent Monopoly In: Post-Print. [Citation analysis] | paper | 0 |
2018 | Does Orphan Drug market exclusivity incentive sustains drug development for rare diseases ? In: Post-Print. [Citation analysis] | paper | 0 |
2018 | Naming institution after neologism as marker of the institutionalization of new discipline In: Post-Print. [Citation analysis] | paper | 0 |
2018 | Delayed Recognition in Science: Different Causes of Sleeping and Awakening of Discoveries In: Post-Print. [Citation analysis] | paper | 0 |
2014 | Ultrasons focalisés de haute intensité : analyse des dynamiques d’innovations In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Medical literature imprinting by pharma ghost writing: a scientometric evaluation In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Mapping scientific dynamics in « Regenerative Medicine » research In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Diffusion of Interventional Radiology and Health Technology Assessment: the case of radiofrequency treatment in oncology In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Towards a Patent landscaping of Regenerative Medicine In: Post-Print. [Citation analysis] | paper | 1 |
2017 | Angiogenesis inhibitors drug pipeline landscape In: Post-Print. [Citation analysis] | paper | 0 |
2017 | Orphan Drug legislation: evaluation of the impact of market exclusivity extension In: Post-Print. [Citation analysis] | paper | 0 |
2017 | Science and Technology Indicators of Microalgae-Based Biofuel Research In: Post-Print. [Citation analysis] | paper | 0 |
2017 | The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature In: Post-Print. [Citation analysis] | paper | 0 |
2017 | The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature.(2017) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
2018 | Impact of Health Technology Assessment on Innovation Diffusion: the case of techniques in Interventional Radiology. In: Post-Print. [Citation analysis] | paper | 0 |
2019 | Market Valuation of FDA Orphan Drug Regulatory Events In: Post-Print. [Citation analysis] | paper | 2 |
2019 | Global overview of patenting landscape in unmanned aerial vehicles. In: Post-Print. [Citation analysis] | paper | 0 |
2019 | Drug Safety scientometrics overview highlights public health issues. In: Post-Print. [Citation analysis] | paper | 0 |
2013 | HTA National Public Policy and Their Socio-Economic Environment: A European Perspective In: Post-Print. [Citation analysis] | paper | 0 |
2019 | R&D incentives and innovation spillovers: evidence from the European orphan drug regulation. In: Post-Print. [Citation analysis] | paper | 0 |
2013 | Analyse sectorielle, technologique et économique, du marché des médicaments orphelins. In: Post-Print. [Citation analysis] | paper | 0 |
2013 | A patent landscaping of medicinal plants extracts In: Post-Print. [Citation analysis] | paper | 0 |
2013 | The scientific-knowledge based institutionalization of Health Technology Assessment: a bibliometric and network analysis In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Website: orphandrugseconomics.org In: Post-Print. [Citation analysis] | paper | 0 |
2016 | Economie de la santé : les médicaments orphelins In: Post-Print. [Citation analysis] | paper | 0 |
2020 | Pourquoi les prix des traitements contre les maladies rares deviennent fous ? In: Post-Print. [Citation analysis] | paper | 0 |
2019 | Atelier Accès à linnovation In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Does scientific knowledge play a role in public policies? A contribution of scientometrics to political science: the case of HTA In: Post-Print. [Citation analysis] | paper | 0 |
2015 | Naissances de la radiologie interventionnelle. Le rôle de Charles T. Dotter In: Post-Print. [Citation analysis] | paper | 0 |
2020 | Impact de la législation européenne des médicaments orphelins sur le marché global du médicament In: Post-Print. [Citation analysis] | paper | 0 |
2020 | Assessment of generic competition for Orphan Drugs marketed in the US (1993-2019) In: Post-Print. [Citation analysis] | paper | 0 |
2020 | Le statut de médicament orphelin est un signal positif pour les investisseurs lors de lintroduction en bourse des sociétés de biotechnologie In: Post-Print. [Citation analysis] | paper | 0 |
2020 | Médicaments orphelins et maladies rares sur Twitter In: Post-Print. [Citation analysis] | paper | 0 |
2021 | Beyond health security dependencies. Rethinking public health and industrial policies construction In: Post-Print. [Citation analysis] | paper | 0 |
2022 | Drug shortages, APIs supply & Pharma Global Value Chain In: Post-Print. [Citation analysis] | paper | 0 |
2013 | Health Technology Assessment Agencies and their economic environment: a European perspective. In: Post-Print. [Citation analysis] | paper | 0 |
2014 | The EUs Government of Pharmaceuticals: Incompleteness Embraced In: Post-Print. [Citation analysis] | paper | 0 |
2017 | Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021. In: Working Papers. [Citation analysis] | paper | 0 |
2015 | La construction des catégories diagnostiques de maladie mentale In: Revue de la Régulation - Capitalisme, institutions, pouvoirs. [Full Text][Citation analysis] | article | 0 |
2021 | Sécurité sanitaire sous dépendance. Une construction politique à repenser In: Revue de la Régulation - Capitalisme, institutions, pouvoirs. [Full Text][Citation analysis] | article | 0 |
2016 | “Sleeping beauty” and her restless sleep: Charles Dotter and the birth of interventional radiology In: Scientometrics. [Full Text][Citation analysis] | article | 12 |
2018 | Delayed recognition of Judah Folkman’s hypothesis on tumor angiogenesis: when a Prince awakens a Sleeping Beauty by self-citation In: Scientometrics. [Full Text][Citation analysis] | article | 9 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team